Molecular methods in the diagnosis and management of chronic hepatitis B

References

• Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis.2, 395–403 (2002).
   PubMed Web of Science ®Google Scholar
• Tiollais P, Charnay P, Vyas GN. Biology of hepatitis B virus. Science213, 406–411 (1981).
   PubMed Web of Science ®Google Scholar
• Lee WM. Hepatitis B virus infection. N. Engl. J. Med.337, 1733–1745 (1997).
   PubMed Web of Science ®Google Scholar
• Neurath AR, Kent SB, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell46, 429–436 (1986).
   PubMed Web of Science ®Google Scholar
• Kann M, Gerlich W. Structure and molecular virology. In: Viral Hepatitis. Zuckerman AJ, Thomas HC (Eds). Churchill Livingstone, London, UK, 77–106 (1998).
   Google Scholar
• Simmonds P. The origin and evolution of hepatitis viruses in humans. J. Gen. Virol.82, 693–712 (2001).
   PubMed Web of Science ®Google Scholar
• Seeger C, Mason WS. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev.64, 51–56 (2000).
   PubMed Web of Science ®Google Scholar
• Newbold JE, Xin H, Tencza M et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J. Virol.69, 3350–3357 (1995).
   PubMed Web of Science ®Google Scholar
• Wright TL, Lau JY. Clinical aspects of hepatitis B virus infection. Lancet342, 1340–1344 (1993).
   PubMed Web of Science ®Google Scholar
• Fattovich G. Natural history and prognosis of hepatitis B. Semin. Liver Dis.23, 47–58 (2003).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology34, 1225–1241 (2001).
   PubMed Web of Science ®Google Scholar
• Manesis EK, Papatheodoridis GV, Sevastianos V, Cholongitas E, Papaioannou C, Hadziyannis SJ. Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am. J. Gastroenterol.98, 2261–2267 (2003).
   PubMed Web of Science ®Google Scholar
• Alter MJ, Hadler SC, Margolis HS et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA263, 1218–1222 (1990).
   PubMed Web of Science ®Google Scholar
• Choi KH, McFarland W, Neilands TB et al. High level of hepatitis B infection and ongoing risk among Asian/Pacific Islander men who have sex with men, San Francisco, 2000–2001. Sex. Transm. Dis.32, 44–48 (2005).
   PubMed Web of Science ®Google Scholar
• Kondili LA, Genovese D, Argentini C et al. Nosocomial transmission in simultaneous outbreaks of hepatitis C and B virus infections in a hemodialysis center. Eur. J. Clin. Microbiol. Infect. Dis.25, 527–531 (2006).
   PubMedGoogle Scholar
• The Incident Investigation Teams and others. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N. Engl. J. Med.336, 178–184 (1997).
   PubMedGoogle Scholar
• Xu DZ, Yan YP, Choi BC et al. Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case–control study. J. Med. Virol.67, 20–26 (2002).
   PubMed Web of Science ®Google Scholar
• Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J. Infect. Dis.170, 1418–1423 (1994).
   PubMed Web of Science ®Google Scholar
• Satake M, Taira R, Yugi H et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion47, 1197–1205 (2007).
   PubMed Web of Science ®Google Scholar
• Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer61, 1942–1956 (1988).
   PubMed Web of Science ®Google Scholar
• Cenac A, Pedroso ML, Djibo A et al. Hepatitis B, C, and D virus infections in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma: a comparative study in Niger. Am. J. Trop. Med. Hyg.52, 293–296 (1995).
   PubMedGoogle Scholar
• Wu HC, Wang Q, Yang HI et al. Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. Cancer Epidemiol. Biomarkers Prev.18, 846–853 (2009).
   PubMed Web of Science ®Google Scholar
• Bedogni G, Miglioli L, Masutti F et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am. J. Gastroenterol.103(9), 2248–2253 (2008).
   PubMedGoogle Scholar
• Pas SD, Fries E, De Man RA et al. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J. Clin. Microbiol.38, 2897–2901 (2000).
   PubMed Web of Science ®Google Scholar
• Ho SK, Chan TM, Cheng IK, Lai KN. Comparison of the second-generation digene hybrid capture assay with the branched-DNA assay for measurement of hepatitis B virus DNA in serum. J. Clin. Microbiol.37, 2461–2465 (1999).
   PubMedGoogle Scholar
• Yao JD, Beld MG, Oon LL et al. Multicenter evaluation of the VERSANT hepatitis B virus DNA 3.0 assay. J. Clin. Microbiol.42(2), 800–880 (2004).
   PubMed Web of Science ®Google Scholar
• Chan HL, Leung NW, Lau TC, Wong ML, Sung JJ. Comparison of three different sensitive assays for hepatitis B virus DNA in monitoring of responses to antiviral therapy. J. Clin. Microbiol.38, 3205–3208 (2000).
   PubMedGoogle Scholar
• Kessler HH, Pierer K, Dragon E et al. Evaluation of a new assay for HBV DNA quantitation in patients with chronic hepatitis B. Clin. Diagn. Virol.9, 37–43 (1998).
   PubMedGoogle Scholar
• Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Evaluation of the COBAS amplicor HBV monitor assay and comparison with the ultrasensitive HBV hybrid capture 2 assay for quantification of hepatitis B virus DNA. J. Clin. Microbiol.43(2), 596–603 (2005).
   PubMedGoogle Scholar
• Kamisango K, Kamogawa C, Sumi M et al. Quantitative detection of hepatitis B virus by transcription-mediated amplification and hybridization protection assay. J. Clin. Microbiol.37, 310–314 (1999).
   PubMed Web of Science ®Google Scholar
• Daniel HD, Fletcher JG, Chandy GM, Abraham P. Quantitation of hepatitis B virus DNA in plasma using a sensitive cost-effective ‘in-house’ real-time PCR assay. Indian J. Med. Microbiol.27(2), 111–115 (2009).
   PubMedGoogle Scholar
• Niesters HG, Krajden M, Cork L et al. A multicenter study evaluation of the digene hybrid capture II signal amplification technique for detection of hepatitis B virus DNA in serum samples and testing of EUROHEP standards. J. Clin. Microbiol.38(6), 2150–2155 (2000).
   PubMedGoogle Scholar
• Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J. Clin. Microbiol.44(4), 1390–1399 (2006).
   PubMedGoogle Scholar
• Stelzl E, Muller Z, Marth E, Kessler HH. Rapid quantification of hepatitis B virus DNA by automated sample preparation and real-time PCR. J. Clin. Microbiol.42(6), 2445–2449 (2004).
   PubMedGoogle Scholar
• Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann. Intern. Med.150(2), 104–110 (2009).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Dieterich DT, Han SH et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol.6(12), 1315–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology50(3), 661–662 (2009).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology45(4), 1056–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J. Gastroenterol. Hepatol.17(4), 409–414 (2002).
   PubMedGoogle Scholar
• Nash K. Telbivudine in the treatment of chronic hepatitis B. Adv. Ther.26(2), 155–169 (2009).
   PubMedGoogle Scholar
• Kwon SY, Park YK, Ahn SH et al. Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J. Virol.84(9), 4494–4503 (2010).
   PubMedGoogle Scholar
• Mondou E, Sorbel J, Anderson J, Mommeja-Marin H, Rigney A, Rousseau F. Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine. Clin. Infect. Dis.41(5), e45–e47 (2005).
   Web of Science ®Google Scholar
• Lim SG, Ng TM, Kung N et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med.166(1), 49–56 (2006).
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Leemans WF, Hansen BE et al. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks. J. Viral Hepat.16(2), 113–120 (2009).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med.359(23), 2442–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology49(5), 1503–1514 (2009).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Kato T, Mizokami M et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J. Hepatol.39(5), 850–855 (2003).
   PubMedGoogle Scholar
• Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology46(1), 254–265 (2007).
   PubMed Web of Science ®Google Scholar
• Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology24(3), 714–717 (1996).
   PubMed Web of Science ®Google Scholar
• Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology27(6), 1711–1716 (1998).
   PubMed Web of Science ®Google Scholar
• Jardi R, Buti M, Rodriguez-Frias F et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods83(1–2), 181–187 (1999).
   PubMedGoogle Scholar
• Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol.38(2), 702–707 (2000).
   PubMed Web of Science ®Google Scholar
• Shih YH, Yeh SH, Chen PJ et al. Hepatitis B virus quantification and detection of YMDD mutants in a single reaction by real-time PCR and annealing curve analysis. Antivir. Ther. (Lond.)13(4), 469–480 (2008).
   PubMedGoogle Scholar
• Bai YJ, Zhao JR, Lv GT, Zhang WH, Wang Y, Yan XJ. Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization. World J. Gastroenterol.9(10), 2344–2347 (2003).
   PubMedGoogle Scholar
• Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol.42(10), 4788–4795 (2004).
   PubMed Web of Science ®Google Scholar
• Wang YZ, Xiao JH, Ruan LH et al. Detection of the rtA181V/T and rtN236T mutations associated with resistance to adefovir dipivoxil using a ligase detection reaction assay. Clin. Chim. Acta408(1–2), 70–74 (2009).
   PubMedGoogle Scholar
• Lee CZ, Lee HS, Huang GT, Yang PM, Sheu JC. Detection of YMDD mutation using mutant-specific primers in chronic hepatitis B patients before and after lamivudine treatment. World J. Gastroenterol.12(33), 5301–5305 (2006).
   PubMedGoogle Scholar
• Jang H, Cho M, Heo J et al. Oligonucleotide chip for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol.42(9), 4181–4188 (2004).
   PubMedGoogle Scholar
• Gaillard RK, Barnard J, Lopez V et al. Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob. Agents Chemother.46(4), 1005–1013 (2002).
   PubMedGoogle Scholar
• Delaney WE 4th, Yang H, Westland CE et al. The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J. Virol.77(21), 11833–11841 (2003).
   PubMed Web of Science ®Google Scholar
• Libbrecht E, Doutreloigne J, Van De Velde H et al. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J. Clin. Microbiol.45(12), 3935–3941 (2007).
   PubMed Web of Science ®Google Scholar
• de Franchis R, Hadengue A, Lau G et al. EASL International Consensus Conference on hepatitis B. 13–14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J. Hepatol.39(Suppl. 1), S3–S25 (2003).
   PubMed Web of Science ®Google Scholar
• Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J. Antimicrob. Chemother.61(4), 766–768 (2008).
   PubMed Web of Science ®Google Scholar
• Chin R, Shaw T, Torresi J et al.In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-β-L-arabinofuranosyluracil. Antimicrob. Agents Chemother.45(9), 2495–2501 (2001).
   PubMed Web of Science ®Google Scholar
• Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T, Thibault V. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir. Antivir. Ther. (Lond.)9(3), 353–363 (2004).
   PubMed Web of Science ®Google Scholar
• Delaney WE 4th, Edwards R, Colledge D et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob. Agents Chemother.45(6), 1705–1713 (2001).
   PubMed Web of Science ®Google Scholar
• Ladner SK, Otto MJ, Barker CS et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob. Agents Chemother.41(8), 1715–1720 (1997).
   PubMed Web of Science ®Google Scholar
• Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother.42(12), 3200–3208 (1998).
   PubMed Web of Science ®Google Scholar
• Yuen LK, Ayres A, Littlejohn M et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res.75(1), 64–74 (2007).
   PubMed Web of Science ®Google Scholar
• Keeffe EB, Zeuzem S, Koff RS et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol.5(8), 890–897 (2007).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology45(4), 1056–1075 (2007).
   PubMed Web of Science ®Google Scholar
• Hou J, Wang Z, Cheng J et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology34(5), 1027–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Allain JP, Belkhiri D, Vermeulen M et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology49(6), 1868–1876 (2009).
   PubMedGoogle Scholar
• Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology34(1), 204–206 (2001).
   PubMed Web of Science ®Google Scholar
• Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med.341, 22–26 (1999).
   PubMed Web of Science ®Google Scholar
• Raimondo G. Occult hepatitis B virus infection and liver disease: fact or fiction? J. Hepatol.34, 471–473 (2001).
   PubMedGoogle Scholar
• Vivekanandan P, Kannangai R, Ray SC, Thomas DL, Torbenson M. Comprehensive genetic and epigenetic analysis of occult hepatitis B from liver tissue samples. Clin. Infect. Dis.46(8), 1227–1236 (2008).
   PubMed Web of Science ®Google Scholar
• Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP. Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J. Hepatol.48(6), 1022–1025 (2008).
   PubMed Web of Science ®Google Scholar
• Toniutto P, Minisini R, Fabris C et al. Occult hepatitis B virus infection in liver transplant recipients with recurrent hepatitis C: relationship with donor age and fibrosis progression. Clin. Transplant.23(2), 184–190 (2009).
   PubMedGoogle Scholar
• Ramia S, Sharara AI, El-Zaatari M, Ramlawi F, Mahfoud Z. Occult hepatitis B virus infection in Lebanese patients with chronic hepatitis C liver disease. Eur. J. Clin. Microbiol. Infect. Dis.27(3), 217–221 (2008).
   PubMed Web of Science ®Google Scholar
• Hou J, Wang Z, Cheng J et al. Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology34(5), 1027–1034 (2001).
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Daniel HD, Kannangai R, Martinez-Murillo F, Torbenson M. Hepatitis B virus replication induces methylation of both host and viral DNA. J. Virol.84(9), 4321–4329 (2010).
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Thomas D, Torbenson M. Methylation regulates hepatitis B viral protein expression. J. Infect. Dis.199(9), 1286–1291 (2009).
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Thomas D, Torbenson M. Hepatitis B viral DNA is methylated in liver tissues. J. Viral Hepat.15(2), 103–107 (2008).
   PubMed Web of Science ®Google Scholar
• Okamoto H, Tsuda F, Sakugawa H et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol.69(Pt 10), 2575–2583 (1988).
   PubMed Web of Science ®Google Scholar
• Norder H, Hammas B, Lofdahl S, Courouce AM, Magnius LO. Comparison of the amino acid sequences of nine different serotypes of hepatitis B surface antigen and genomic classification of the corresponding hepatitis B virus strains. J. Gen. Virol.73(Pt 5), 1201–1208 (1992).
   PubMedGoogle Scholar
• Stuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J. Gen. Virol.81, 67–74 (2000).
   PubMed Web of Science ®Google Scholar
• Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J. Gen. Virol.83, 2059–2073 (2002).
   PubMed Web of Science ®Google Scholar
• Norder H, Hammas B, Lee SD et al. Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J. Gen. Virol.74(Pt 7), 1341–1348 (1993).
   PubMedGoogle Scholar
• Schaefer S. Hepatitis B virus taxonomy and hepatitis B virus genotypes. World J. Gastroenterol.13(1), 14–21 (2007).
   PubMedGoogle Scholar
• Pollack JR, Ganem D. An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol.67, 3254–3263 (1993).
   PubMedGoogle Scholar
• Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology122(7), 1756–1762 (2002).
   PubMed Web of Science ®Google Scholar
• Nakayoshi T, Maeshiro T, Nakasone H et al. Difference in prognosis between patients infected with hepatitis B virus with genotype B and those with genotype C in the Okinawa Islands: a prospective study. J. Med. Virol.70, 350–354 (2003).
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology118, 554–559 (2000).
   PubMed Web of Science ®Google Scholar
• Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J. Clin. Microbiol.40, 1207–1209 (2002).
   PubMed Web of Science ®Google Scholar
• Devarbhavi HC, Cohen AJ, Patel R, Wiesner RH, Dickson RC, Ishitani MB. Preliminary results: outcome of liver transplantation for hepatitis B virus varies by hepatitis B virus genotype. Liver Transpl.8(6), 550–555 (2002).
   PubMedGoogle Scholar
• Flink HJ, van Zonneveld M, Hansen BE et al. Treatment with Peg-interferon α-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol.101(2), 297–303 (2006).
   PubMed Web of Science ®Google Scholar
• Zhao H, Kurbanov F, Wan MB et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-α-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin. Infect. Dis.44(4), 541–548 (2007).
   PubMed Web of Science ®Google Scholar
• Zollner B, Petersen J, Schroter M, Laufs R, Schoder V, Feucht HH. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet357(9260), 934–935 (2001).
   PubMed Web of Science ®Google Scholar
• Kao JH, Liu CJ, Chen DS. Hepatitis B viral genotypes and lamivudine resistance. J. Hepatol.36(2), 303–304 (2002).
   PubMed Web of Science ®Google Scholar
• Yu MW, Yeh SH, Chen PJ et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl Cancer Inst.97(4), 265–272 (2005).
   PubMed Web of Science ®Google Scholar
• Vivekanandan P, Bissett S, Ijaz S et al. Correlation between hepatitis B genotypes, 1896 precore mutation, virus loads and liver dysfunction in an Indian population. Indian J. Gastroenterol.27(4), 142–147 (2008).
   PubMedGoogle Scholar
• Vivekanandan P, Abraham P, Sridharan G et al. Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin. Infect. Dis.38(9), e81–e86 (2004).
   Google Scholar
• Naito H, Hayashi S, Abe K. Rapid and specific genotyping system for hepatitis B virus corresponding to six major genotypes by PCR using type-specific primers. J. Clin. Microbiol.39(1), 362–364 (2001).
   PubMed Web of Science ®Google Scholar
• Liu WC, Lindh M, Buti M et al. Genotyping of hepatitis B virus – genotypes A to G by multiplex polymerase chain reaction. Intervirology51(4), 247–252 (2008).
   PubMedGoogle Scholar
• Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus – large-scale analysis using a new genotyping method. J. Infect. Dis.175(6), 1285–1293 (1997).
   PubMedGoogle Scholar
• Hussain M, Chu CJ, Sablon E, Lok AS. Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J. Clin. Microbiol.41(8), 3699–3705 (2003).
   PubMed Web of Science ®Google Scholar
• Kato H, Orito E, Sugauchi F et al. Frequent coinfection with hepatitis B virus strains of distinct genotypes detected by hybridization with type-specific probes immobilized on a solid-phase support. J. Virol. Methods110(1), 29–35 (2003).
   PubMedGoogle Scholar
• Yeh SH, Tsai CY, Kao JH et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J. Hepatol.41(4), 659–666 (2004).
   PubMedGoogle Scholar
• Tang XR, Zhang JS, Zhao H, Gong YH, Wang YZ, Zhao JL. Detection of hepatitis B virus genotypes using oligonucleotide chip among hepatitis B virus carriers in Eastern China. World J. Gastroenterol.13(13), 1975–1979 (2007).
   PubMedGoogle Scholar
• Pas SD, Tran N, de Man RA, Burghoorn-Maas C, Vernet G, Niesters HG. Comparison of reverse hybridization, microarray, and sequence analysis for genotyping hepatitis B virus. J. Clin. Microbiol.46(4), 1268–1273 (2008).
   PubMedGoogle Scholar
• Simmonds P, Midgley S. Recombination in the genesis and evolution of hepatitis B virus genotypes. J. Virol.79(24), 15467–15476 (2005).
   PubMedGoogle Scholar
• Suwannakarn K, Tangkijvanich P, Theamboonlers A, Abe K, Poovorawan Y. A novel recombinant of hepatitis B virus genotypes G and C isolated from a Thai patient with hepatocellular carcinoma. J. Gen. Virol.86(Pt 11), 3027–3030 (2005).
   PubMedGoogle Scholar
• Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet2, 588–591 (1989).
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Stemler M, Bonino F et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J. Hepatol.10, 258–261 (1990).
   PubMed Web of Science ®Google Scholar
• Rezende RE, Fonseca BA, Ramalho LN et al. The precore mutation is associated with severity of liver damage in Brazilian patients with chronic hepatitis B. J. Clin. Virol.32(1), 53–59 (2005).
   PubMedGoogle Scholar
• Vivekanandan P, Abraham P, Sridharan G et al. High frequency of the 1896 precore mutation in patients and blood donors with hepatitis B virus infection from the Indian subcontinent. Mol. Diagn.8(1), 51–56 (2004).
   PubMedGoogle Scholar
• Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J. Infect. Dis.179(4), 775–782 (1999).
   PubMedGoogle Scholar
• Song BC, Cui XJ, Shin JW et al. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in lamivudine-resistant chronic hepatitis B patients. Intervirology53(4), 203–210 (2010).
   PubMedGoogle Scholar
• Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol.68, 8102–8110 (1994).
   PubMed Web of Science ®Google Scholar
• Gunther S, Piwon N, Will H. Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) –> T, A(1762) –> T and G(1764) –>A mutations in the core promoter. J. Gen. Virol.79(Pt 2), 375–380 (1998).
   PubMedGoogle Scholar
• Lindh M, Hannoun C, Dhillon AP, Norkrans G, Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J. Infect. Dis.179(4), 775–782 (1999).
   PubMedGoogle Scholar
• Lin CL, Liao LY, Wang CS et al. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int.25(3), 564–570 (2005).
   PubMedGoogle Scholar
• Chen CH, Changchien CS, Lee CM et al. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case–control study. J. Infect. Dis.198(11), 1634–1642 (2008).
   PubMed Web of Science ®Google Scholar
• Song BC, Cui XJ, Shin JW et al. Response to adefovir depends on mutation patterns in precore region, basal core promoter and reverse transcriptase, and on-treatment responses in lamivudine-resistant chronic hepatitis B patients. Intervirology53(4), 203–210 (2010).
   PubMedGoogle Scholar
• Ozgenc O, Ozacar T, Erensoy S et al. Clinical significance of basal core promoter and precore mutations in chronic hepatitis B. Hepatogastroenterology54(80), 2319–2323 (2007).
   PubMedGoogle Scholar
• Carman WF, Zanetti AR, Karayiannis P et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet336, 325–329 (1990).
   PubMed Web of Science ®Google Scholar
• Oon CJ, Lim GK, Ye Z et al. Molecular epidemiology of hepatitis B virus vaccine variants in Singapore. Vaccine13, 699–702 (1995).
   PubMed Web of Science ®Google Scholar
• Ijaz S, Torre F, Tedder RS, Williams R, Naoumov NV. Novel immunoassay for the detection of hepatitis B surface ‘escape’ mutants and its application in liver transplant recipients. J. Med. Virol.63, 210–216 (2001).
   PubMedGoogle Scholar
• Tian Y, Xu Y, Zhang Z et al. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J. Clin. Microbiol.45(9), 2971–2978 (2007).
   PubMedGoogle Scholar
• Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology130(4), 1153–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang H, Gu C et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl Cancer Inst.101(15), 1066–1082 (2009).
   PubMedGoogle Scholar
• Hsieh YH, Su IJ, Wang HC et al. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis25(10), 2023–2032 (2004).
   PubMed Web of Science ®Google Scholar
• Niitsuma H, Ishii M, Saito Y et al. Prevalence of precore-defective mutant of hepatitis B virus in HBV carriers. J. Med. Virol.46, 397–402 (1995).
   PubMedGoogle Scholar
• Protzer-Knolle U, Knolle P, Schiedhelm E, Meyer zum Buschenfelde KH, Gerken G. Semiquantitative assessment of pre-core stop-codon mutant and wildtype hepatitis B virus during the course of chronic hepatitis B using a new PCR-based assay. Arch. Virol.141, 2091–2101 (1996).
   PubMedGoogle Scholar
• Ren XD, Lin SY, Wang X, Zhou T, Block TM, Su YH. Rapid and sensitive detection of hepatitis B virus 1762T/1764A double mutation from hepatocellular carcinomas using LNA-mediated PCR clamping and hybridization probes. J. Virol. Methods158(1–2), 24–29 (2009).
   PubMedGoogle Scholar
• Mendy ME, Kaye S, Le Roux E et al. Application of a novel, rapid, and sensitive oligonucleotide ligation assay for detection of cancer-predicting mutations in the precore and basal core promoter of hepatitis B virus. J. Clin. Microbiol.46(8), 2723–2730 (2008).
   PubMedGoogle Scholar
• Zhang M, Gong Y, Osiowy C, Minuk GY. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. Hepatology36(3), 723–728 (2002).
   PubMedGoogle Scholar
• Olivero A, Ciancio A, Abate ML, Gaia S, Smedile A, Rizzetto M. Performance of sequence analysis, INNO-LiPA line probe assays and AFFIGENE assays in the detection of hepatitis B virus polymerase and precore/core promoter mutations. J. Viral Hepat.13(6), 355–362 (2006).
   PubMedGoogle Scholar
• Shen FC, Su IJ, Wu HC et al. A pre-S gene chip to detect pre-S deletions in hepatitis B virus large surface antigen as a predictive marker for hepatoma risk in chronic hepatitis B virus carriers. J. Biomed. Sci.16, 84 (2009).
   PubMedGoogle Scholar
• Vivekanandan P, Singh OV. High-dimensional biology to comprehend hepatocellular carcinoma. Expert Rev. Proteomics5(1), 45–60 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HS, Han KH, Ahn SH et al. Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir. Ther.10(3), 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Yeon JE, Yoo W, Hong SP et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut55(10), 1488–1495 (2006).
   PubMed Web of Science ®Google Scholar
• Block TM, Comunale MA, Lowman M et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc. Natl Acad. Sci. USA102(3), 779–784 (2005).
   PubMed Web of Science ®Google Scholar
• Wu FX, Wang Q, Zhang ZM et al. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Cancer Lett.279(2), 163–170 (2009).
   PubMed Web of Science ®Google Scholar
• Feng JT, Liu YK, Song HY et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics5(17), 4581–4588 (2005).
   PubMed Web of Science ®Google Scholar
• Li N, Long Y, Fan X et al. Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J. Exp. Clin. Cancer Res.28, 122 (2009).
   PubMedGoogle Scholar
• Ma Y, Yu J, Chan HL et al. Glucose-regulated protein 78 is an intracellular antiviral factor against hepatitis B virus. Mol. Cell Proteomics8(11), 2582–2594 (2009).
   PubMed Web of Science ®Google Scholar
• Feng H, Wang M, Chen WN. iTRAQ-coupled 2D LC-MS/MS analysis of secreted proteome of HBV-replicating HepG2 cells: potential in biomarkers for prognosis of HCC. Curr. Microbiol.61(4), 280–284 (2010).
   PubMedGoogle Scholar
• Kim SY, Lee PY, Shin HJ et al. Proteomic analysis of liver tissue from HBx-transgenic mice at early stages of hepatocarcinogenesis. Proteomics9(22), 5056–5066 (2009).
   PubMedGoogle Scholar
• Vivekanandan P, Torbenson M. Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas. Mod. Pathol.21(6), 670–675 (2008).
   PubMedGoogle Scholar
• Niu D, Sui J, Zhang J, Feng H, Chen WN. iTRAQ-coupled 2-D LC-MS/MS analysis of protein profile associated with HBV-modulated DNA methylation. Proteomics9(15), 3856–3868 (2009).
   PubMed Web of Science ®Google Scholar
• Kim YJ, Lee HS, Yoon JH et al. Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection. Hum. Mol. Genet.12(19), 2541–2546 (2003).
   PubMed Web of Science ®Google Scholar
• Thio CL, Carrington M, Marti D et al. Class II HLA alleles and hepatitis B virus persistence in African Americans. J. Infect. Dis.179(4), 1004–1006 (1999).
   PubMed Web of Science ®Google Scholar
• Fletcher GJ, Gnanamony M, Samuel P et al. Association of mannose-binding lectin polymorphisms and HBV outcome in a South Indian population. Int. J. Immunogenet.37(3), 177–184 (2010).
   PubMedGoogle Scholar
• Lee HW, Lee JI, Um SH et al. Combination therapy of thymosin a-1 and lamivudine for HBeAg positive chronic hepatitis B: a prospective randomized, comparative pilot study. J. Gastroenterol. Hepatol.23(5), 729–735 (2008).
   PubMed Web of Science ®Google Scholar
• Deng L, Li G, Xi L et al. Hepatitis B virus inhibition in mice by lentiviral vector mediated short hairpin RNA. BMC Gastroenterol.9, 73 (2009).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wong ML, Bowden S et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology128(7), 1890–1897 (2005).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Wong DK, Sum SS et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am. J. Gastroenterol.100(5), 1099–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Margeridon-Thermet S, Shulman NS, Ahmed A et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J. Infect. Dis.199(9), 1275–1285 (2009).
   PubMed Web of Science ®Google Scholar